EG 427 has announced the successful closing of a €27 million Series B financing round co-led by Andera Partners and Bpifrance – as part of the InnoBio investment strategy.   

The proceeds from the financing will be used to fund the Phase Ib/IIa development of EG 427’s lead genetic medicine product, EG110A, for the treatment of neurogenic detrusor overactivity (NDO) in spinal cord injury (SCI) patients.  

Philippe Chambon, Chief Executive Officer at EG 427, said: “Genetic medicine solutions have the potential to address major medical needs affecting large patient population with chronic diseases. Initially, our focus is on pathologies in neuro-urology. This field is currently underserved and lacks significant recent medical innovations, despite its huge costs to the healthcare systems. This funding allows us to advance our first programme focussed on dysfunctions of the bladder, such as neurogenic bladder, through its initial clinical trial. This first human study, currently in progress, will provide a read on safety and possibly early efficacy.” 

EG110A is a genetic medicine utilising a non-replicating HSV-1 vector, which has been designed to selectively silence the signals of key bladder sensory neurons responsible for the bladder muscle overactivity, whilst preserving bladder voiding function.  

NDO is a common urinary bladder dysfunction caused by SCI and other neurodegenerative diseases, such as multiple sclerosis or Parkinson’s disease. 

An Investigational New Drug (IND) application for EG110A was cleared by the US Food and Drug Administration (FDA) in June 2024. 

The financing will also support expansion of EG 427’s pipeline with several therapeutic vectors based on its HERpes Modular Expression System (HERMES) technology.

Diana Spencer, Senior Digital Content Editor, DDW